| Ident. | Authors (with country if any) | Title |
|---|
| 000596 |
Charles J. Ryan [États-Unis] ; Mark Rosenthal [Australie] ; Siobhan Ng [Australie] ; Joshi Alumkal [États-Unis] ; Joel Picus [États-Unis] ; Gwenaëlle Gravis [France] ; Karim Fizazi [France] ; Frédéric Forget [Belgique] ; Jean-Pascal Machiels [Belgique] ; Sandy Srinivas [États-Unis] ; MIN ZHU [États-Unis] ; RUI TANG [États-Unis] ; Kellys. Oliner [États-Unis] ; YIZHOUJIANG [États-Unis] ; Elwyn Loh [États-Unis] ; Sarita Dubey [États-Unis] ; Winald R. Gerritsen [Pays-Bas] | Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone |
| 000653 |
Luis Fayad [États-Unis] ; Fritz Offner [Belgique] ; Mitchell R. Smith [États-Unis] ; Gregor Verhoef [Belgique] ; Peter Johnson [Royaume-Uni] ; Jonathan L. Kaufman [États-Unis] ; Ama Rohatiner [Royaume-Uni] ; Anjali Advani [États-Unis] ; James Foran [États-Unis] ; Georg Hess [Allemagne] ; Bertrand Coiffier [France] ; Myron Czuczman [États-Unis] ; Eva Gine [Espagne] ; Simon Durrant [Australie] ; Michelle Kneissl [États-Unis] ; Kenneth T. Luu [États-Unis] ; Steven Y. Hua [États-Unis] ; Joseph Boni [États-Unis] ; Erik Vandendries [États-Unis] ; Nam H. Dang [États-Unis] | Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab |
| 000B84 |
Christophe Biot [France] ; Cyrille Y. Botte [France, Australie] ; Faustine Dubar [France] ; Eric Marechal [France] | Paludisme: Recherche de nouvelles approches thérapeutiques ciblant l'apicoplaste, un organite cellulaire d'origine algale |
| 000D01 |
James I. Macrae [Australie] ; Eric Marechal [France] ; Christophe Biot [France] ; Cyrille Y. Botte [France, Australie] | The Apicoplast: A Key Target to Cure Malaria |
| 001531 |
Sigrun Reumann [Norvège] | Toward a definition of the complete proteome of plant peroxisomes: Where experimental proteomics must be complemented by bioinformatics |
| 001993 |
Trina J. Stewart [Australie] ; Mark J. Smyth [Australie] | Improving cancer immunotherapy by targeting tumor-induced immune suppression |
| 002301 |
Christian W. Gruber [Autriche] ; Markus Muttenthaler [Australie] ; Michael Freissmuth [Autriche] | Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors |
| 002590 |
Peter E. Czabotar [Australie] ; Guillaume Lessene [Australie] | Bcl-2 Family Proteins as Therapeutic Targets |
| 002E61 |
Ana S. Guerreiro [Suisse] ; Sarah Fattet [France, Suisse] ; Barbara Fischer [Suisse] ; Tarek Shalaby [Suisse] ; Shaun P. Jackson [Australie] ; Simone M. Schoenwaelder [Australie] ; Michael A. Grotzer [Suisse] ; Olivier Delattre [France] ; Alexandre Arcaro [Suisse] | Targeting the PI3K p110α Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration |
| 003017 |
Raymond S. Norton [Australie] ; Stefan I. Mcdonough [États-Unis] | Peptides Targeting Voltage-Gated Calcium Channels |
| 003038 |
Mona Shehata [Australie] ; Ivan Bieche [France] ; Rose Boutros [Australie] ; Judith Weidenhofer [Australie] ; Susan Fanayan [Australie] ; Lisa Spalding [Australie] ; Nikolajs Zeps [Australie] ; Karen Byth [Australie] ; Robert K. Bright [États-Unis] ; Rosette Lidereau [France] ; Jennifer A. Byrne [Australie] | Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52 |
| 003137 |
Neil P. Shah [États-Unis, Corée du Sud, France, Brésil, Argentine, Mexique, Russie, Australie, Allemagne] ; Hagop M. Kantarjian ; Dong-Wook Kim ; Delphine Rea ; Pedro E. Dorlhiac-Llacer ; Jorge H. Milone ; Jorge Vela-Ojeda ; Richard T. Silver ; H. Jean Khoury ; Aude Charbonnier ; Nina Khoroshko ; Ronald L. Paquette ; Michael Deininger ; Robert H. Collins ; Irma Otero ; Timothy Hughes ; Eric Bleickardt ; Lewis Strauss ; Stephen Francis ; Andreas Hochhaus | Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia |
| 003763 |
Timothy I. Webb [Australie] ; Joseph W. Lynch [Australie] | Molecular pharmacology of the glycine receptor chloride channel |
| 003D36 |
A. J. Scheen [Belgique] ; Prakash Deedwania [États-Unis] ; Philip Barter [Australie] ; Rafael Carmena [Espagne] ; Jean-Charles Fruchart [France] ; Scott M. Grundy [États-Unis] ; Steven Haffner [États-Unis] ; Jorin J. P. Kastelein [Pays-Bas] ; John C. Larosa [États-Unis] ; Holly Schachner [États-Unis] ; James Shepherd [Royaume-Uni] ; David D. Waters [États-Unis] | Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome : analysis of the Treating to New Targets study. Commentary |
| 004503 |
Robert A. Rastall [Royaume-Uni] ; Glenn R. Gibson [Royaume-Uni] ; Harsharnjit S. Gill [Australie] ; Fransisco Guarner [Espagne] ; Todd R. Klaenhammer [États-Unis] ; Bruno Pot [France] ; Gregor Reid [Canada] ; Ian R. Rowland [Royaume-Uni] ; Mary Ellen Sanders [États-Unis] | Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: An overview of enabling science and potential applications |
| 004916 |
Christina L. Van Broekhoven [Australie] ; Christopher R. Parish [Australie] ; Caroline Demangel [France] ; Warwick J. Britten [Australie] ; Joseph G. Altin [Australie] | Targeting dendritic cells with antigen-containing liposomes: A highly effective procedure for induction of antitumor immunity and for tumor immunotherapy |
| 005875 |
Alex Duval [France] ; Sandra Rolland [France] ; Aurore Compoint [France] ; Emmanuel Tubacher [France] ; Barry Lacopetta [Australie] ; Gilles Thomas [France] ; Richard Hamelin [France] | Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers |
